Zora Biosciences Oy, a diagnostics discovery company specializing in cardiovascular disease, and Mayo Medical Laboratories recently signed an agreement to collaborate on a new test for plasma ceramides.
Cytochrome P450 2C19 (encoded by the gene CYP2C19) is a liver enzyme that participates in the activation of the anticoagulant clopidogrel (Plavix) and metabolism of other drugs, such as citalopram. As a result, Clopidrigrel may be less effective in altering platelet activity in those people, who may remain at risk for heart attack, stroke, and cardiovascular death.
Quadricuspid aortic valve (QAV) is a rare congenital cardiac defect. Mayo Clinic researchers conducted a study to determine QAV frequency in a large echocardiography database, characterize associated cardiovascular abnormalities, and describe long-term outcomes. The study was published in the Circulation journal.
Bioprosthetic valve thrombosis (BPVT) is considered uncommon, as it is often unrecognized. According to recent data, BPVT responds to vitamin K antagonists, emphasizing the need for reliable diagnosis. Mayo Clinic researchers conducted a study to determine the diagnostic features of BPVT and to formulate a diagnostic model for BPVT. The study was published in the Journal of the American College of Cardiology.
To address potential confounders in the observed sex differences in aortic valve weight and aortic valve calcium burden, Mayo Clinic researchers conducted a study to describe sex-related differences in clinical and echocardiographic characteristics of patients undergoing surgery for pure AS, determine clinical, echocardiographic, and valve morphology determinants of AVW, and correlate AVW with pre-operative aortic valve CT calcium score. The study was published in the European Heart Journal.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory protein that is produced by macrophages in the vascular intima and is present in high concentrations on the plaques that build up in blood vessels. Several studies have shown that patients with high levels of Lp-PLA2 in the blood are at higher risk of a cardiovascular event such as myocardial infarction or stroke. Mayo Medical Laboratories offers the recently Food and Drug Administration (FDA)-cleared test PLACA / Lipoprotein-Associated Phospholipase A2 Activity, Serum, which produces reliable and reproducible results.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker of atherosclerosis and is often referred to by the trademark name “The PLAC Test.” Lp-PLA2 is an enzyme involved with atherosclerotic plaque formation and elevations in plasma Lp-PLA2 concentration and activity are associated with increased risk of cardiovascular disease.
In a study published in the Journal of Cardiac Failure, Mayo Clinic researchers assessed the value of serial measurements of soluble suppression of tumorigenicity 2 (ST2) and galectin-3 (Gal3) when added to natriuretic peptides and cTnT to identify the risk for heart failure over time.
Pediatric heart failure is a rare but serious condition with a variety of underlying etiologies ranging from congenital heart disease to neuromuscular disorders. Due to the rareness of biomarkers available in pediatric heart failure, Mayo Clinic researchers sought to provide a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. The study was recently published in the journal Clinical Biochemistry.
A 67-year-old white man with a history of coronary artery disease status, post–3-vessel coronary artery bypass grafting, and ischemic heart disease, presented with fatigue and dyspnea on exertion for six months. Read this post to learn more about the case and the diagnosis.
On Wednesday, July 29, more than 100 AACC attendees attended a Breakfast Workshop panel discussion of the emerging science and clinical laboratory testing options related to lipoprotein-associated phospholipase (LP-PLA2) activity.
Inherited cardiovascular diseases have historically been identified most frequently through the patient’s family history. Now, next-generation sequencing technology has taken genetic testing to a new level, allowing assessment of multiple genes and mutations with one test.
Mayo Clinic’s launch of eight new next-generation sequencing (NGS) panels is intended to improve the lives of patients and families living with inherited cardiac conditions by assisting in the diagnosis and management of these complex disorders. The NGS panels provide a genetic evaluation for patients with a personal or family history suggestive of an inherited cardiac condition.